Bio of Severin Schwan
Dr. Severin Schwan is the company’s CEO, executive director, and chairman of the corporate executive committee. From March 4, 2008, he served as Roche Holding AG’s Chief Executive Officer and Chairman of the Corporate Executive Committee.
Prior to January 1, 2006, he served as the Company’s Chief Executive Officer, President, and Member of the Corporate Executive Committee for the division Roche Diagnostics. He worked as a Trainee in Corporate Finance for Roche Basel between 1993 and 1995.
He served as Roche Brussels’ Head of Finance & Administration from 1995 to 1998. Dr. Schwan served as Head Finance & Informatics and Member of the Executive Board at Roche Grenzach in Germany from 1998 to 2000. He served as the Head of Global Finance & Services for Roche Diagnostics in Basel from 2000 until 2004.
Dr. Schwan has served on the boards of Chugai Pharmaceuticals in Japan since 2009 and the Mayor of Shanghai’s International Business Leaders Advisory Council (IBLAC). Dr. Schwan completed his economics studies at the Universities of Oxford, York, and Innsbruck. He graduated from Innsbruck with a degree in economics.
He earned a law degree in 1991 after completing his studies at the University of Innsbruck. Later, in 1993, Dr. Schwan earned a doctorate in law from the University of Innsbruck and pursued research studies at the Catholic University of Louvain in Belgium.
How much does Severin Schwan make?
Severin Schwan earns a total of $11,516,900 at Roche AG as Chairman of the Corporate Executive Committee, Chief Executive Officer, and Executive Director. At Roche AG, no executives receive higher salaries.
When was Severin Schwan born?
53-year-old Severin Schwan has served as Roche AG’s chief executive officer, executive director, and chairman of the corporate executive committee since 2013. At Roche AG, there are 18 senior executives and 6 junior executives. Fritz Gerber, 90, the Honorary Chairman of the Board, is the senior executive at Roche Holding AG.
What is Roche AG’s mission?
Roche Holding AG operates in the German, Swiss, and international markets for prescription drugs and diagnostics.
Leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, transplantation, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, and transplantation are among the medical conditions for which it provides pharmaceutical products.
For indications including cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, cancer, and women’s health, the company also provides in vitro diagnostics solutions. Additionally, it provides test kits, reagents, consumables, and diagnostic equipment for use in the broad research market.
The business has a COVID-19 collaboration with Gilead Sciences, Inc.; a license and collaboration agreement with Shionogi & Co., Ltd. to create and market Xofluza; and a collaboration agreement with SemaThera Inc. to create biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases.
and collaborates with Surface Oncology, Inc. to assess SRF388 as well as Affimed N.V. to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR-expressing solid tumors. Additionally, it has clinical collaborations with Carrick Therapeutics, Ltd.
To assess a novel combination of Carrick’s samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer; Zur Rose Group AG to assist people with diabetes and their caregivers in managing their daily therapy; and Venatorx Pharmaceuticals, Inc. to conduct research on, characterize, and develop novel small molecule drugs. Founded in 1896, Roche Holding AG is headquartered in Basel, Switzerland.
What does Roche AG’s logo look like?
Roche AG executives and stock owners
Roche AG executives and other stock owners filed with the SEC include:
Severin Schwan, Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director Dr. Severin Schwan Ph.D., CEO & Exec. Director William Anderson, Member of the Corporate Executive Committee, Chief Executive Officer Roche Pharmaceuticals William N. Anderson, Chief Exec. Officer of Roche Pharmaceuticals Alan Hippe, Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer Christoph Franz, Non-Executive Independent Chairman of the Board Dr. Alan Hippe, Chief Financial & Information Officer Cristina Wilbur, Member of the Corporate Executive Committee, Head Group Human Resources Cristina A. Wilbur, Chief People Officer Thomas Schinecker, Chief Exec. Officer of Roche Diagnostics Thomas Schinecker, Member of the Corporate Executive Committee, Chief Executive Officer Roche Diagnostics Andre Hoffmann, Non-Executive Independent Vice Chairman of the Board Claudia Suessmuth Dyckerhoff, Non-Executive Independent Director Julie Brown, Non-Executive Independent Director Richard Lifton, Non-Executive Independent Director Bernard Poussot, Non-Executive Independent Director Anita Hauser, Non-Executive Independent Director Paul Bulcke, Non-Executive Independent Director Hans Clevers, Director Karl Mahler, Head of Investor Relations Patrick Frost, Director Joerg Duschmale, Director Per-Olof Attinger, Secretary to the Corporate Executive Committee Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genentech Research & Early Development (gRED) Barbara Schaedler, Member of the Enlarged Corporate Executive Committee, Head Group Communications James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) Claudia Boeckstiegel, Member of the Corporate Executive Committee, General Counsel Pascale Schmidt, Chief Compliance Officer Fritz Gerber, Honorary Chairman of the Board Ehab Yousef, Head of Middle East Sub-Region 1 Dr. Nicolas Dunant, Head of Group Media Relations Pascale Schmidt, Chief Compliance Officer Claudia Bockstiegel, Gen. Counsel